Sartorius Stedim Announces Expansion Of Sartorius Stedim Cellca

• Biopharma provider purchases property in Science Park III of Ulm
• Laboratory and office facility to be constructed on the site by 2019

Sartorius Stedim Cellca based near Ulm in southern Germany, continues on the growth track. At the end of November, the company in its eleventh year since its founding purchased property of more than 6,000 square meters at Ulm’s Science Park III at Eselsberg to build a new laboratory and office complex. The new facility, which will approximately double the company’s space, is scheduled to be completed by the end of 2019. So far, Sartorius Stedim Cellca has been located in a rented building in Laupheim.

“Our new site’s proximity to universities and research institutes in Ulm’s Scientific Park offers an excellent environment to promote our growing business for which we are also seeking additional highly qualified staff,“ commented Managing Director Hugo de Wit.

“Besides the advantages offered by this research environment, its conveniently accessible location was also decisive for us. We need to be within easy reach of our international customers,” continued de Wit. Sartorius Stedim Cellca develops and markets platform technologies, such as cell lines and associated services, for customers in the biopharmaceutical industry. Since 2015, the company has been part of the biopharma supplier Sartorius Stedim Biotech and currently employs 80 people.

About Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. In 2015, the company employed approx. 4,200 people, and earned sales revenue of 884.3 million euros. For more information, visit www.sartorius.com.